CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases

Summary

This is a single-arm, open-label, single-center, phase I/II study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive relapsed or refractory Malignant Hematologic Diseases

Timeline

Start

2023-04-30

Primary completion

2026-04-25

Completion

2027-04-25

Drugs

Indications